Klaria Pharma Holding AB (6FN) AI Stock Analysis

Klaria Pharma Holding AB

(Frankfurt:6FN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Buccal film platformKlaria has a defined technology platform rather than an undifferentiated drug-development approach. Applying buccal thin-film delivery across therapeutic areas could support multiple product programs and create reusable development expertise if candidates progress successfully.

Negative Factors

Minimal revenue and persistent lossesThe company has not yet demonstrated a sustainable commercial earnings base: TTM revenue is minimal while losses remain very large and margins are sharply negative. Persistent losses reduce internal funding capacity and leave future value dependent on successful product progress or external financing.

Klaria Pharma Holding AB (6FN) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 12.10M
Dividend Yield: ―
Average Volume (3M): 500
Price to Earnings (P/E): -3.2
Beta (1Y): 1.22
Revenue Growth: -98.95%
EPS Growth: 36.43%
Country: Germany
Employees: 4
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Klaria Pharma Holding AB Business Overview & Revenue Model

Company Description

Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. W...

Klaria Pharma Holding AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:6FN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:ALZCUR	55Neutral	SEK 882.54M	42.87	65.99%	―	―	―
SE:XBRANE	53Neutral	SEK 291.57M	-5.90	-11.52%	―	-38.80%	-120.18%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ISOFOL	49Neutral	SEK 383.95M	-5.99	-54.41%	―	―	32.79%
SE:ELIC	48Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:IRLAB.A	42Neutral	SEK 310.81M	-3.21	-97.06%	―	4.74%	66.33%

* Healthcare Sector Average

Performance Comparison

DE:6FN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:6FN	Klaria Pharma Holding AB	0.04	0.00	0.00%
SE:ALZCUR	AlzeCure Pharma AB	6.40	4.51	238.45%
SE:XBRANE	Xbrane Biopharma AB	14.15	3.35	31.02%
SE:ISOFOL	Isofol Medical AB	1.20	0.51	74.89%
SE:ELIC	Elicera Therapeutics AB	2.65	-3.44	-56.47%
SE:IRLAB.A	IRLAB Therapeutics AB Class A	2.09	-0.40	-15.90%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Klaria Pharma Holding AB AI Stock Analysis